Sagimet BiosciencesSTU:0O2 +9.12%10 3-Year Dividend Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 96 Biotechnology companies, Sagimet Biosciences ranks worse than 1041665.63% on this metric.
The historical rank and industry rank for Sagimet Biosciences's 3-Year Dividend Growth Rate or its related term are showing as below:
STU:0O2's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.1 * Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences 3-Year Dividend Growth Rate Related Terms>
STU:0O2 vs EDIT, AUTL, FBRX: 3-Year Dividend Growth Rate Comparison
For the Biotechnology subindustry, Sagimet Biosciences's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences 3-Year Dividend Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 0.00% mean?
Sagimet Biosciences (STU:0O2) has a 3-Year Dividend Growth Rate of 0.00% as of Mar. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #999999 out of 96 companies in the Biotechnology industry.
Is Sagimet Biosciences' 3-Year Dividend Growth Rate too high?
Sagimet Biosciences' current 3-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, Sagimet Biosciences ranks #999999 out of 96 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' 3-Year Dividend Growth Rate compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #999999 out of 96 companies for 3-Year Dividend Growth Rate. This places Sagimet Biosciences in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 5.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Biotechnology company?
The median 3-Year Dividend Growth Rate among Biotechnology companies is 5.10, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median 3-Year Dividend Growth Rate is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current 3-Year Dividend Growth Rate of 0.00%. The current 3-Year Dividend Growth Rate is 0.00%. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current 3-Year Dividend Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 